Last reviewed · How we verify
Placebo for guselkumab
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
At a glance
| Generic name | Placebo for guselkumab |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (guselkumab) by comparison. Any observed effects in the placebo group are attributed to natural disease progression, regression to the mean, or the placebo effect itself. Placebos are essential for blinded, randomized controlled trials to isolate the true therapeutic benefit of the investigational agent.
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants (PHASE3)
- Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease (PHASE3)
- Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis (PHASE3)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (PHASE3)
- A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis (PHASE2)
- An Explorative Psoriasis Biomarker Study (NA)
- Multi-Center PAMPA Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for guselkumab CI brief — competitive landscape report
- Placebo for guselkumab updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI